Shares of OptimizeRx Co. (NASDAQ:OPRX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $16.00.
Several brokerages recently weighed in on OPRX. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price target on shares of OptimizeRx in a research note on Monday, April 1st. JMP Securities reiterated a “market outperform” rating and issued a $16.00 price target on shares of OptimizeRx in a research note on Friday, June 21st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $13.00 price objective on shares of OptimizeRx in a research note on Wednesday, May 15th.
Check Out Our Latest Stock Analysis on OptimizeRx
Institutional Trading of OptimizeRx
OptimizeRx Trading Down 3.1 %
Shares of OPRX opened at $10.00 on Wednesday. OptimizeRx has a 1-year low of $6.92 and a 1-year high of $16.65. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average price is $11.11 and its 200-day moving average price is $12.80. The firm has a market capitalization of $182.70 million, a price-to-earnings ratio of -9.80 and a beta of 1.28.
OptimizeRx (NASDAQ:OPRX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). OptimizeRx had a negative net margin of 23.10% and a negative return on equity of 6.96%. The firm had revenue of $19.69 million for the quarter, compared to the consensus estimate of $18.66 million. During the same period in the previous year, the firm posted ($0.34) earnings per share. Sell-side analysts anticipate that OptimizeRx will post -0.42 EPS for the current year.
About OptimizeRx
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Stories
- Five stocks we like better than OptimizeRx
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Business Services Stocks Investing
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Calculate Options Profits
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.